Radiotherapy for laryngeal squamous cell carcinoma: current standards

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin.59, 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin. Oncol.21, 281–288 (1994).
   PubMed Web of Science ®Google Scholar
• Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat. Res.114, 15–60 (2003).
   PubMedGoogle Scholar
• Hoffman HT, Porter K, Karnell LH et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope116, 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Tamura Y, Tanaka S, Asato R et al. Therapeutic outcomes of laryngeal cancer at Kyoto, University Hospital for 10 years. Acta Otolaryngol. Suppl.557, 62–65 (2007).
   Google Scholar
• Pfister DG, Laurie SA, Weinstein GS et al. American Society of Clinical Oncology clinical practice guidelines for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J. Clin. Oncol.24, 3693–3704 (2006).
   PubMed Web of Science ®Google Scholar
• Olsen KD. Re-examining the treatment of advanced laryngeal cancer. Head Neck32, 1–7 (2010).
   PubMed Web of Science ®Google Scholar
• Holsinger FC, Nussenbaum B, Nakayama M et al. Current concepts and new horizons in conservation laryngeal surgery: an important part of multidisciplinary care. Head Neck32, 656–665 (2010).
   PubMedGoogle Scholar
• Forastiere AA. Larynx preservation and survival trends: should there be concern? Head Neck32, 14–17 (2010).
   PubMedGoogle Scholar
• The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med.324, 1685–1690 (1991).
   PubMed Web of Science ®Google Scholar
• Chen AY, Schrag N, Hao Y et al. Changes in treatment of advanced laryngeal cancer 1985–2001. Otolaryngol. Head Neck Surg.135, 831–837 (2006).
   PubMed Web of Science ®Google Scholar
• Silver CE, Beitler JJ, Shaha AR, Rinalod A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur. Arch. Otorhinolaryngol.266, 1333–1352 (2009).
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl Cancer Inst.88, 890–899 (1996).
   PubMed Web of Science ®Google Scholar
• Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol.3, 693–701 (2002).
   PubMed Web of Science ®Google Scholar
• Van den Bogaert W, Van der Leest A, Rijnders A et al. Does tumour control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer? Radiother. Oncol.36, 177–182 (1995).
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 & 7 randomised controlled trial. Lancet362, 933–940 (2003).
   PubMed Web of Science ®Google Scholar
• Overgaard J, Mohanti BK, Begum N et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol.11(6), 553–560 (2010).
   PubMed Web of Science ®Google Scholar
• Dische S, Saunders M, Barrett A et al. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol.44, 123–136 (1997).
   PubMed Web of Science ®Google Scholar
• Fu KK, Clery M, Ang KK et al. Randomized Phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. Int. J. Radiat. Oncol. Biol. Phys.32, 589–597 (1995).
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation therapy for head and neck squamous cell carcinomas: first report of RTOG 90-03. Int. J. Radiat. Oncol. Biol. Phys.48, 7–16 (2000).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet368, 843–584 (2006).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M et al. Concurrent chemoradiotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med.349, 2091–2098 (2003).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Maor M, Weber R et al. Long-term results of Intergroup RTOG 91-11: a Phase III trial to preserve the larynx – induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc. Am. Soc. Clin. Oncol.24 (2006) (Abstract 5517).
   Google Scholar
• Pignon JP, Bourhis J, Domenge C, Designe L; on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet355, 949–955 (2000).
   PubMed Web of Science ®Google Scholar
• Bourhis J, Amand C, Pignon JP; on behalf of the MACH-NC Collaborative Group. Update of the MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. J. Clin. Oncol.22(14S), 5505 (2004).
   Google Scholar
• Pignon JP, le Maître A, Maillard E, Bourhis J; on behalf of the MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol.92, 4–14 (2009).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Milicic B, Dagovic A et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, non-metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol.22, 3540–3548 (2004).
   PubMed Web of Science ®Google Scholar
• Hoebers FJP, Heemsbergen W, Balm AJM et al. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother. Oncol.85, 42–47 (2007).
   PubMedGoogle Scholar
• Bourhis J, Sire C, Lapeyre M et al. Accelerated radiotherapy and/or concomitant chemotherapy in locally advanced head and neck squamous cell carcinoma: results of a GORTEC randomized trial. Radiother. Oncol.90, S6–S7 (2009).
   Google Scholar
• Nuyts S, Dirix P, Hermans R et al. Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer. Head Neck29, 720–730 (2007).
   PubMedGoogle Scholar
• Nuyts S, Dirix P, Clement PMJ et al. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys.73, 1088–1095 (2009).
   PubMedGoogle Scholar
• Laccourreye O, Bassot V, Brasnu D, Laccourreye H. Chemotherapy combined with conservation surgery in the treatment of early larynx cancer. Curr. Opin. Oncol.11, 200–203 (1999).
   PubMedGoogle Scholar
• Sessions DG, Lenox J, Spector GJ et al. Management of T3N0M0 glottic carcinoma: therapeutic outcomes. Laryngoscope112, 1281–1288 (2002).
   PubMed Web of Science ®Google Scholar
• Hinerman RW, Mendenhall WM, Morris CG et al. T3 and T4 true vocal cord squamous carcinomas treated with external beam irradiation: a single institution’s 35-year experience. Am. J. Clin. Oncol.30, 181–185 (2007).
   PubMedGoogle Scholar
• Becker M. Neoplastic invasion of laryngeal cartilage: radiologic diagnosis and therapeutic implications. Eur. J. Radiol.33, 216–229 (2000).
   PubMed Web of Science ®Google Scholar
• Samant S, Robbins KT, Kumar P et al. Bone or cartilage invasion by advanced head and neck cancer: intra-arterial supradose cisplatin chemotherapy and concomitant radiotherapy for organ preservation. Arch. Otolaryngol. Head Neck Surg.127, 1451–1456 (2001).
   PubMedGoogle Scholar
• Rodriguez CP, Adelstein DJ, Rybicki LA et al. Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck30, 1535–1542 (2008).
   PubMedGoogle Scholar
• Knab BR, Salama JK, Solanki A et al. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann. Oncol.19, 1650–1654 (2008).
   PubMedGoogle Scholar
• Worden FP, Moyer J, Lee JS et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope199, 1510–1517 (2009).
   Google Scholar
• Mendenhall WM, Mancuso AA, Hinerman RW et al. Multidisciplinary management of laryngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.69, S12–S14 (2007).
   Google Scholar
• Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res.62, 7350–7356 (2002).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol.11, 21–28 (2010).
   PubMed Web of Science ®Google Scholar
• Curran D, Giralt J, Harari PM et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol.25, 2191–2197 (2007).
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL et al. An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patienst with unresectable squamous cell head and neck cancer. J. Clin. Oncol.21, 92–98 (2003).
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Rolland F, Tesselaar M et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J. Natl Cancer Inst.101, 142–452 (2009).
   PubMedGoogle Scholar
• List MA, Stracks J, Colangelo L et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J. Clin. Oncol.18, 877–884 (2000).
   PubMed Web of Science ®Google Scholar
• Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol.26, 3582–3589 (2008).
   PubMed Web of Science ®Google Scholar
• Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer107, 2525–2534 (2006).
   PubMed Web of Science ®Google Scholar
• Platteaux N, Dirix P, Dejaeger E, Nuyts S. Dysphagia in head and neck cancer patients treated with chemoradiotherapy. Dysphagia25(2), 139–152 (2009).
   PubMedGoogle Scholar
• Eisbruch A, Lyden T, Bradford CR et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys.53, 23–28 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Frank C, Moltz CC et al. Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.61, 772–778 (2005).
   PubMed Web of Science ®Google Scholar
• Caudell JJ, Schaner PE, Meredith RF et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.73, 410–415 (2009).
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Doornaert P, Rietveld DHF et al. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother. Oncol.90, 189–195 (2009).
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Doornaert P, Verdonck-de Leeuw IM et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J. Clin. Oncol.26, 3770–3776 (2008).
   PubMed Web of Science ®Google Scholar
• Tsao AS, Garden AS, Kies MS et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol.24, 4163–4169 (2006).
   PubMedGoogle Scholar
• Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncol.11, 85–91 (2010).
   PubMed Web of Science ®Google Scholar
• Lambert L, Fortin B, Soulières D et al. Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int. J. Radiat. Oncol. Biol. Phys.76, 398–402 (2009).
   PubMedGoogle Scholar
• Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of laryngeal cancer. Arch. Otolaryngol. Head Neck Surg.124, 964–971 (1998).
   PubMedGoogle Scholar
• Hanna E, Sherman A, Cash D et al. Quality of life after treatment for patients following total laryngectomy versus chemoradiation for laryngeal preservation. Arch. Otolaryngol. Head Neck Surg.129, 733–738 (2003).
   PubMedGoogle Scholar
• Fung K, Lyden TH, Lee J et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int. J. Radiat. Oncol. Biol. Phys.63, 1395–1399 (2005).
   PubMedGoogle Scholar
• Veldeman L, Madani I, Hulstaert F et al. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol.9, 367–375 (2008).
   PubMed Web of Science ®Google Scholar
• Nutting C, A’Hern R, Rogers MS et al.; on behalf of the PARSPORT Trial Management Group. First results of a Phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). J. Clin. Oncol.27(18 Suppl.) (2009) (Abstract LBA6006).
   PubMedGoogle Scholar
• Eisbruch A, Levendag PC, Feng FY et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int. J. Radiat. Oncol. Biol. Phys.69, S40–S42 (2007).
   Web of Science ®Google Scholar
• Dirix P, Nuyts S. Value of intensity-modulated radiotherapy in stage IV head and neck squamous cellcarcinoma. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.10.018 (2010) (Epub ahead of print).
   Google Scholar
• Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst.86, 265–272 (1994).
   PubMed Web of Science ®Google Scholar
• Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J. Cancer83, 1594–1598 (2000).
   PubMed Web of Science ®Google Scholar
• Urba S, Wolf G, Eisbruch A et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J. Clin. Oncol.24, 593–598 (2006).
   PubMed Web of Science ®Google Scholar
• Posner MR, Glisson B, Frenette G et al. Multicenter Phase I–II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol.19, 1096–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, Van Herpen C et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) as neo-adjuvant chemotherapy for non-resectable locally advanced head and neck cancer (LAHNC): a Phase III of the EORTC head and neck cancer group (EORTC # 24971). J. Clin. Oncol.22, S5508 (2004).
   Google Scholar
• Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol.23, 8636–8645 (2005).
   PubMed Web of Science ®Google Scholar
• Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst.101, 498–506 (2009).
   PubMed Web of Science ®Google Scholar
• Hitt R, Grau J, Lopez-Pousa A et al. Final results of a randomized Phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J. Clin. Oncol.27(15 Suppl.) (2009) (Abstract 6009).
   Google Scholar
• Lefebvre J, Pointreau Y, Rolland F et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized Phase II TREMPLIN study. J. Clin. Oncol.27(15 Suppl.) (2009) (Abstract 6010).
   Google Scholar
• Haigentz M Jr, Silver CE, Hartl DM et al. Chemotherapy regimens and treatment protocols for laryngeal cancer. Expert Opin. Pharmacother.11, 1305–1316 (2010).
   PubMedGoogle Scholar